MA27799A1 - DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa - Google Patents

DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa

Info

Publication number
MA27799A1
MA27799A1 MA28588A MA28588A MA27799A1 MA 27799 A1 MA27799 A1 MA 27799A1 MA 28588 A MA28588 A MA 28588A MA 28588 A MA28588 A MA 28588A MA 27799 A1 MA27799 A1 MA 27799A1
Authority
MA
Morocco
Prior art keywords
factor
compounds
factor viia
disorders
formula
Prior art date
Application number
MA28588A
Other languages
English (en)
Inventor
Matthias Urmann
Hans Matter
Marc Nazare
Volkmar Wehner
David William Will
Kurt Ritter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA27799A1 publication Critical patent/MA27799A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I) dans laquelle R0, R1, R2, R3, Q, V, G et M ont la signification donnée dans les revendications. Lesdits composés sont des composés pharmacologiquement actifs, ils présentent un fort effet antithrombotique et peuvent par exemple servir à la thérapie et à la prophylaxie de troubles cardiovasculaires tels que des maladies thromboemboliques et des resténoses. Lesdits composés sont par ailleurs des inhibiteurs réversibles du facteur Xa (FXa) et/ou du facteur VIIa (FVIIa) des enzymes de coagulation sanguine, et peuvent être employés dans le cas de troubles caractérisés par une activité indésirable du facteur Xa et/ou du facteur VIIa ou dans le traitement ou la prévention de troubles nécessitant une inhibition du facteur Xa et/ou du facteur VIIa. L'invention concerne par ailleurs des procédés de fabrication des composés représentés par la formule (I), leur utilisation, notamment en tant que principes actifs dans des agents pharmaceutiques, et des préparations pharmaceutiques contenant lesdits composés.
MA28588A 2003-05-19 2005-11-08 DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa MA27799A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03011304A EP1479680A1 (fr) 2003-05-19 2003-05-19 Derivés d' azaindole en tant qu'inhibiteurs du facteur Xa

Publications (1)

Publication Number Publication Date
MA27799A1 true MA27799A1 (fr) 2006-03-01

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28588A MA27799A1 (fr) 2003-05-19 2005-11-08 DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa

Country Status (25)

Country Link
EP (2) EP1479680A1 (fr)
JP (1) JP4733642B2 (fr)
KR (1) KR20060012636A (fr)
CN (1) CN100347172C (fr)
AR (1) AR045682A1 (fr)
AU (1) AU2004238500B2 (fr)
BR (1) BRPI0410429A (fr)
CA (1) CA2526084A1 (fr)
CL (1) CL2004001079A1 (fr)
CR (1) CR8088A (fr)
EC (1) ECSP056179A (fr)
HK (1) HK1089175A1 (fr)
MA (1) MA27799A1 (fr)
MX (1) MXPA05012156A (fr)
NO (1) NO20055911L (fr)
NZ (1) NZ543669A (fr)
OA (1) OA13169A (fr)
PE (1) PE20050554A1 (fr)
RS (1) RS20050857A (fr)
RU (1) RU2330853C2 (fr)
TN (1) TNSN05296A1 (fr)
TW (1) TW200510411A (fr)
UA (1) UA86767C2 (fr)
WO (1) WO2004101563A1 (fr)
ZA (1) ZA200508150B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629232A1 (fr) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Derives d'azaindole-2-carboxamide
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2885301A1 (fr) 2012-08-17 2015-06-24 Bayer CropScience AG Amides d'acide azaindole-carboxylique et thiocarboxylique comme insecticides et acaricides
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
DE69532754T2 (de) 1994-04-26 2005-03-10 Aventis Pharmaceuticals, Inc. Faktor xa inhibitoren
ATE260103T1 (de) * 1997-12-19 2004-03-15 Schering Ag Ortho-anthranilamide derivate als antikoagulantien
PT1042287E (pt) * 1997-12-24 2005-08-31 Aventis Pharma Gmbh Derivados de indole como inibidores do factor xa
EP0987274A1 (fr) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Inhibiteurs du facteur VIIa
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1216228B1 (fr) * 1999-09-17 2008-10-29 Millennium Pharmaceuticals, Inc. BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
WO2002000651A2 (fr) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
BR0207952A (pt) * 2001-03-07 2004-07-27 Pfizer Prod Inc Moduladores da atividade de receptores de quimiocina
WO2002080853A2 (fr) * 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Inhibiteurs heterocycliques fusionnes du facteur xa
EP1314733A1 (fr) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides comme inhibiteurs du facteur Xa
WO2003053361A2 (fr) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. COMPOSES D'ANTAGONISTES SELECTIFS DE PYRROLOPYRIMIDINE A2b, LEUR SYNTHESE ET LEUR UTILISATION
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
BRPI0410429A (pt) 2006-06-06
NZ543669A (en) 2008-12-24
EP1636226B1 (fr) 2014-10-15
CN100347172C (zh) 2007-11-07
CN1791601A (zh) 2006-06-21
UA86767C2 (ru) 2009-05-25
NO20055911L (no) 2006-02-10
JP2006528214A (ja) 2006-12-14
JP4733642B2 (ja) 2011-07-27
AU2004238500A1 (en) 2004-11-25
OA13169A (en) 2006-12-13
KR20060012636A (ko) 2006-02-08
MXPA05012156A (es) 2006-08-18
AR045682A1 (es) 2005-11-09
CL2004001079A1 (es) 2005-04-08
PE20050554A1 (es) 2005-08-04
TW200510411A (en) 2005-03-16
HK1089175A1 (en) 2006-11-24
TNSN05296A1 (en) 2007-07-10
ECSP056179A (es) 2006-08-30
EP1636226A1 (fr) 2006-03-22
CA2526084A1 (fr) 2004-11-25
RU2005139557A (ru) 2007-06-27
EP1479680A1 (fr) 2004-11-24
RU2330853C2 (ru) 2008-08-10
AU2004238500B2 (en) 2010-07-22
CR8088A (es) 2006-09-22
RS20050857A (en) 2007-11-15
WO2004101563A1 (fr) 2004-11-25
ZA200508150B (en) 2007-02-28

Similar Documents

Publication Publication Date Title
MA27798A1 (fr) DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa
TNSN04091A1 (en) Indole-2-carboxamides as factor xa inhibitors
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
ATE429432T1 (de) Indazolderivate als faktor xa-inhibitoren
ATE293617T1 (de) Oxybenzamidderivate als faktor-xa-inhibitoren
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA27146A1 (fr) INHIBITEURS DU FACTEUR Xa ET D'AUTRES SERINE-PROTEASES IMPLIQUEES DANS LA CASCADE DE LA COAGULATION.
TNSN02022A1 (fr) Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant
TWI222865B (en) Pharmaceutical composition for treatment of thromboembolic disorder or atherosclerosis or to inhibit blood coagulation
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
MA27799A1 (fr) DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa
KR20070049251A (ko) 조직 인자 길항제 및 그의 사용 방법
JP2007506720A (ja) 治療的処置
AR026257A1 (es) N-guanidinoalquilamidas, su preparacion, su uso y composiciones farmaceuticas que las contienen
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TH65773A (th) อนุพันธ์อินโดลชนิดใหม่ใช้เป็นสารยับยั้ง Xa แฟกเตอร์
JO2467B1 (en) New indole derivatives as an inhibitor of Xa
EP1829535A2 (fr) Antagonistes de facteur de tissus et leurs procédés d'utilisation
TH91551B (th) การเตรียมและการใช้ของสารประกอบเป็นตัวยับยั้งแอสพาร์ทิล โปรตีเอส
CA2076050A1 (fr) Esters d'alkyliques ramifies d'acides 4-bis(chloroethyl)aminophenylalkylcarboxyliques pour le traitement des tumeurs primaires et metastasiques du systeme lymphatique, ainsi que des cancers du sein et des ovaires
MA28302A1 (fr) Derives de sulfonamides pour le traitement de maladies